Want to join the conversation?
$GILD 2Q15 Call: Following the nearly 70,000 patients in 1Q15, more than 60,000 additional patients started therapy on a Gilead hepatitis C product during 2Q15. This represents Gilead’s market share of over 90% of all HCV patients, with Harvoni alone representing approx. 85% of all patients captured in the standard third-party tracking data.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!